Gut microbiota in kidney disease and hypertension
- PMID: 29496593
- DOI: 10.1016/j.phrs.2018.02.028
Gut microbiota in kidney disease and hypertension
Abstract
The human gut microbiota is being composed of more than one hundred trillion microbial cells, including aerobic and anaerobic species as well as gram-positive and negative species. Animal based evidence suggests that the change of normal gut microbiota is responsible for several clinical implications including blood pressure increase and kidney function reduction. Trimethylamine-N-Oxide, short-chain fatty acids and inflammatory factors are originated from the gut microbes and may induce changes in arteries, kidneys and blood pressure. Prebiotics and probiotics change the gut microbiota and may reduce high blood pressure and ameliorate chronic kidney disease suggesting a new treatment target in patients for the initial stages of hypertension concomitant with other life style changes such as increased physical exercise and weight reduction to reduce cardiovascular disease complications.
Keywords: Gut dysbiosis; Gut microbiota; Hypertension; Kidney-disease; Microbiome.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.Pharmacol Res. 2019 Mar;141:366-377. doi: 10.1016/j.phrs.2019.01.019. Epub 2019 Jan 10. Pharmacol Res. 2019. PMID: 30639376 Review.
-
The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus.Int Urol Nephrol. 2018 Aug;50(8):1453-1466. doi: 10.1007/s11255-018-1873-2. Epub 2018 May 4. Int Urol Nephrol. 2018. PMID: 29728993 Review.
-
[Pathomechanism and treatment of gut microbiota dysbiosis in chronic kidney disease and interventional effects of Chinese herbal medicine].Zhongguo Zhong Yao Za Zhi. 2017 Jul;42(13):2425-2432. doi: 10.19540/j.cnki.cjcmm.20170609.014. Zhongguo Zhong Yao Za Zhi. 2017. PMID: 28840678 Review. Chinese.
-
Gut microbiota, hypertension and chronic kidney disease: Recent advances.Pharmacol Res. 2019 Jun;144:390-408. doi: 10.1016/j.phrs.2018.01.013. Epub 2018 Jan 31. Pharmacol Res. 2019. PMID: 29378252 Review.
-
Gut microbiome in chronic kidney disease: challenges and opportunities.Transl Res. 2017 Jan;179:24-37. doi: 10.1016/j.trsl.2016.04.007. Epub 2016 Apr 30. Transl Res. 2017. PMID: 27187743 Free PMC article. Review.
Cited by
-
The modulation of gut microbiota by herbal medicine to alleviate diabetic kidney disease - A review.Front Pharmacol. 2022 Nov 14;13:1032208. doi: 10.3389/fphar.2022.1032208. eCollection 2022. Front Pharmacol. 2022. PMID: 36452235 Free PMC article. Review.
-
Toll-like receptor 4 mutation mitigates gut microbiota-mediated hypertensive kidney injury.Pharmacol Res. 2024 Aug;206:107303. doi: 10.1016/j.phrs.2024.107303. Epub 2024 Jul 11. Pharmacol Res. 2024. PMID: 39002869 Free PMC article.
-
An Integrated Multi-Disciplinary Perspectivefor Addressing Challenges of the Human Gut Microbiome.Metabolites. 2020 Mar 6;10(3):94. doi: 10.3390/metabo10030094. Metabolites. 2020. PMID: 32155792 Free PMC article. Review.
-
Bovine serum albumin aggravates macrophage M1 activation and kidney injury in heterozygous Klotho-deficient mice via the gut microbiota-immune axis.Int J Biol Sci. 2021 Feb 2;17(3):742-755. doi: 10.7150/ijbs.56424. eCollection 2021. Int J Biol Sci. 2021. PMID: 33767585 Free PMC article.
-
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD).J Clin Transl Endocrinol. 2024 Apr 2;36:100341. doi: 10.1016/j.jcte.2024.100341. eCollection 2024 Jun. J Clin Transl Endocrinol. 2024. PMID: 38616864 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical